Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small cell lung cancer

被引:81
作者
Borner, MM
Brousset, P
Pfanner-Meyer, B
Bacchi, M
Vonlanthen, S
Hotz, MA
Altermatt, HJ
Schlaifer, D
Reed, JC
Betticher, DC
机构
[1] Univ Bern, CH-3010 Bern, Switzerland
[2] Hop Purpan, Anat Pathol Lab, F-31059 Toulouse, France
[3] Swiss Inst Appl Canc Res, CH-3008 Bern, Switzerland
[4] Burnham Inst, La Jolla, CA 92037 USA
关键词
non-small-cell lung cancer; p53; Bcl-2; Mcl-1; Bax; Bak;
D O I
10.1038/sj.bjc.6690152
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteins of the Bcl-2 family as well as p53 are important regulators of apoptosis. Alterations in the expression of these proteins can contribute to the formation of cancer, as well as influence tumour response to chemo- and radiotherapy. We used antibodies specific for the human Bcl-2, Mcl-1, Bax, Bak and p53 proteins to examine the expression of these apoptosis-regulating genes in 49 archival specimens of patients with radically resected non-small-cell lung cancer (NSCLC). Tumour cells containing immunostaining for the antiapoptotic proteins Bcl-2 and Mcl-1 were present in 31% and 58% of the cases evaluated, respectively, whereas immunopositivity for the proapoptotic proteins Bax and Bak was found in 47% and 58% of the samples. p53 immunopositivity was detected in 61% of the samples. The expression of Bcl-2 and p53 and the expression of Mcl-1. and Bax showed a positive association (P = 0.02 and P = 0.06 respectively), whereas the expression of Bax was inversely related to p53 (P = 0.008). The expression of Bcl-2 had a negative influence on relapse-free survival in this population of primary resected NSCLC patients (P = 0.02). The expression of 953 and Bcl-2 was significantly associated with metastasis-free survival (P < 0.01). Only patients with p53-positive tumours developed metastases during the follow-up period. Our results establish the frequent expression of the Bcl-2 family proteins Bcl-2, Mcl-1, Bax and Bak in NSCLC. It can be expected that Bcl-2 family members have no straightforward impact on clinical outcome in this disease because their interactions in the regulation of apoptosis are complex.
引用
收藏
页码:952 / 958
页数:7
相关论文
共 39 条
[31]  
MIYASHITA T, 1994, CANCER RES, V54, P3131
[32]   Immunocytochemical markers in stage I lung cancer: Relevance to prognosis [J].
Pastorino, U ;
Andreola, S ;
Tagliabue, E ;
Pezzella, F ;
Incarbone, M ;
Sozzi, G ;
Buyse, M ;
Menard, S ;
Pierotti, M ;
Rilke, F .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2858-2865
[33]   BCL-2 PROTEIN IN NON-SMALL-CELL LUNG-CARCINOMA [J].
PEZZELLA, F ;
TURLEY, H ;
KUZU, I ;
TUNGEKAR, MF ;
DUNNILL, MS ;
PIERCE, CB ;
HARRIS, A ;
GATTER, KC ;
MASON, DY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (10) :690-694
[34]   What is an apoptotic index measuring? A commentary [J].
Potten, CS .
BRITISH JOURNAL OF CANCER, 1996, 74 (11) :1743-1748
[35]  
QUINLAN DC, 1992, CANCER RES, V52, P4828
[36]   Double identity for proteins of the Bcl-2 family [J].
Reed, JC .
NATURE, 1997, 387 (6635) :773-776
[37]  
SILVESTRINI R, 1994, J NATL CANCER I, V86, P469
[38]  
TORMANEN U, 1995, CANCER RES, V55, P5595
[39]  
*UICC AM JOINT COM, 1987, MAN STAG CANC